Introduction
It is well known that adherence of bacteria to host tissue cells is a prerequisite for colonization and a causative factor in bacterial pathogenesis. The colonization of periodontal pathogens on gingival tissues and agglutination of erythrocytes is critical in the pathogenic process of periodontal disease. Porphyromonas gingivalis, an important pathogen in adult periodontitis, has many potentially virulent factors that have been implicated as participants in the progression of periodontal disease (1, 2) . It has been reported that P. gingivalis has a high adherence activity to erythrocytes and epithelial cells (3) . Proteolytic enzymes such as gingipains are known as important virulent factors in pathological events during development and the progression of periodontitis (4) . Interestingly these proteases have catalytic domain of protease with hemagglutinin-/adhesin domains (4). Further, protoheme, which is derived from erythrocytes in the natural niche of the organism (5) , is an absolute requirement for the growth of P. gingivalis (6) . Additionally, the proteinase-hemagglutinin complexes may have important roles in the uptake of hemin, which is a vital metabolite of P. gingivalis, via hemagglutination and the subsequent hemolysis of erythrocytes (7) .
Recently, we cloned the gene encoding the130-kDa hemagglutinin domain (130-kDa HMGD) and identified the functional motifs of hemagglutination. The gene families specifying this motif that are found in the P. gingivalis chromosome and encode many hemagglutinin molecules and/or hemagglutinin-related proteases (8) . As the development of passive immunization progresses for periodontitis, it should be noted that P. gingivalis attachment to erythrocytes is an important initial step in the expression of hemolytic activity. In order to clarify the role of hemagglutinin domains in hemolysis and to develop the passive-immunotherapy, r130-kDa HMGD on hemolytic activity. The antibody significantly inhibited the hemolytic activity of P. gingivalis whole cells both in a dose-and a time-dependent manner. However, non-specific mouse IgG did not inhibit the activity (Fig 3) . Discussion The r130-kDa HMGD was purified as a single band in SDS-PAGE (data not shown) and immunized to rabbits. The antibody obtained recognized the 43 and 49-kDa major bands and not the 130-kDa band in P. gingivalis cell extracts and a single band of r130-kDa HMGD. Chandad and Mouton (10) first identified a non-fimbrial and cellbound hemagglutinin (HA-Ag2) associated with P.
gingivalis, and found that the monospecific polyclonal antiserum against HA-Ag2 inhibited hemagglutination. This antibody also recognized the 43 and 49-kDa bands in the outer membrane preparations of P. gingivalis cells. Our antibody against r130-kDa HMGD showed similar Western blot profiles as the antibody against HA-Ag2. These findings suggest that 130-kDa HMGD may be the same molecule as HA-Ag2. Further, this 130-kDa hemagglutinin molecule may be processed or modified in P. gingivalis cells, and functionally expressed as 43 and 49-kDa bands in P. gingivalis cells.
Next, we examined whether the antibody against r130-kDa HMGD could inhibit the hemagglutinating activity of whole P. gingivalis cells. The results showed that the antibody inhibited the hemagglutinating activity of P. gingivalis cells, whereas, pre-immune antiserum and nonspecific IgG did not. The antibody also significantly inhibited the hemolytic activity of P. gingivalis cells in a dose-dependent manner.
We performed a homology analysis using the DNA sequence data and found the 14 registered genes (7). Based on the protein structure, these genes included prtK (from the P. gingivalis strain, W50), prtP (W12), kgp (W83, 381), rgp-1 (H66), prtR (W50), prpR1 (W50), prtH (W83), prtRII (381), rgp2 (H66), rgpB (381), HagD (381), and HagA (381) (7). The complete nucleotide sequencing of DNA fragment encoding 130-kDa HMGD revealed the presence of an insertion sequence similar to insertion sequence (IS) 1126 next to the gene coding for 130kDa-HMGD (7). Since the IS has the ability to move on a chromosome accompanying a particular gene, it is likely that this IS may help spread the gene coding for the hemagglutinin domain throughout the P. gingivalis chromosome. This would contribute to high hemagglutinating activity and cell attachment, and along with the hemolytic activity may transform this bacterium to a more virulent strain. Curtis et al. (11) also pointed out that an adherence and antigenic determinant of the Arg-gingipain of P. gingivalis is present on multiple gene products. Since protoheme is an indispensable nutrient of P.
gingivalis, it seems reasonable to assume that the bacteria lyse erythrocytes through bleeding in the periodontal pocket, thereby degrading hemoglobin and releasing heme. Recently, Nakayama et al. (12) reported that the hemoglobin receptor domain was found in several P. gingivalis proteases including Arg-gingipain, Lys-gingipain and hemagglutinin hagA. Furthermore, defects in hemoglobin adsorption and heme accumulation were observed in a Lys-gingipain deficient mutant (13) . We found that-the hemoglobin receptor domain was located in 130-kDa HMGD (7). This finding is consistent with the concept that, prior to agglutinating erythrocytes through functional motif stretches positioned within the hemoglobin receptor domain, attachment of P. gingivalis onto the erythrocyte cell surface may occur. Once the erythrocytes aggregate, then the hemoglobin receptor domain may function under the aid of the protease. This gene structure seems to be ideal in this bacterium for growth in the periodontal pockets and may obtain heme molecules as an iron source. Passive immunization approaches against oral infectious diseases have been developed (14) . Patients with periodontitis, who harbored P. gingivalis in their subgingival plaque, were clinically treated to suppress any detectable P. gingivalis, and then the monoclonal antibody against P. gingivalis cells was applied to their periodontal pockets. Such treatment significantly reduced the recolonization of P. gingivalis for up to 9-months (15) . When considering passive immunization against periodontal diseases, the pathological focus should be on gingival tissues. Application of a specific antibody that neutralizes bacterial agglutination and hemolytic activity can provide a practical and satisfactory treatment. The antibody presented here may be useful in the development of the passive immunization as well as in the assessment of the treatment of periodontal diseases caused by P. gingivalis infection.
